The Lancet Diabetes and Endocrinology : Impact Factor & More
eISSN: 2213-8595pISSN: 2213-8587
Share this on:
Key Metrics
CiteScore 
49.2
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SNIP
9
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
The Lancet Diabetes and Endocrinology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2013 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Diabetes and Endocrinology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in The Lancet Diabetes and Endocrinology
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
- 7 Aug 2026
- The lancet. Diabetes & endocrinology
Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty.
- 3 Aug 2026
- The lancet. Diabetes & endocrinology
Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Out of touch medical care.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Diabetic foot ulcer prevention in Kuwait.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
- 7 Aug 2026
- The lancet. Diabetes & endocrinology
Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty.
- 3 Aug 2026
- The lancet. Diabetes & endocrinology
Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Out of touch medical care.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Diabetic foot ulcer prevention in Kuwait.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
- 1 Aug 2026
- The lancet. Diabetes & endocrinology
FAQs on The Lancet Diabetes and Endocrinology
How long has The Lancet Diabetes and Endocrinology been actively publishing? 
What is the publishing frequency of The Lancet Diabetes and Endocrinology?
How many articles did The Lancet Diabetes and Endocrinology publish last year?
What is the eISSN & pISSN for The Lancet Diabetes and Endocrinology?
What is Citescore for The Lancet Diabetes and Endocrinology?
What is SNIP score for The Lancet Diabetes and Endocrinology?
Who is the publisher of The Lancet Diabetes and Endocrinology?
